Targeted Strategies for Today's Evolving Markets

MissionIR Blog

Growing Customer Base, Distribution Deal Fuel Continued Top-Line Growth for OxySure Systems, Inc. (OXYS), Says Zacks Analyst

OxySure Systems, a medical technology company focused on the design, manufacture and distribution of specialty respiratory and medical solutions, and developer of a proprietary process to produce medically pure (USP) oxygen from inert powders, was recently the topic of a Seeking Alpha article discussing the company’s trek toward profitability.

To read the article in its entirety visit

OxySure November 14 reported its third-quarter financial results, posting revenues of $546,000, a stunning increase of 428 percent compared to revenues in the comparable quarter of last year and an increase of 15 percent from the second quarter of 2013.

Zacks analyst Jason Napodano, CFA, in his article notes that OXYS revenues topped expectations by $100,000, and that the firm expects the company to enter into the fourth quarter and 2014 with continued top-line growth.

In explaining supporting factors for this forecast, Napodano highlights OXYS’ 2013 partnerships and distribution agreements:

• March 2013 – deal with Aero Healthcare includes purchase order of at least 4,500 units of Model 615
• May 2013 – distributing deal with Medizon B.V. includes minimum purchase order of 2,250 units of Model 615
• May 2013 – approval to market the Model 615 and related accessories in Israel
• June 2013 – distribution agreement with Aventric Technologies

Napodano also takes into consideration several other company achievements, as well as in further detail discusses OXYS’ financial performance and growing customer base.

In conclusion, he writes, “It is likely, given the current trajectory of the top-line, that OxySure can achieve cash flow positive operations by the end of 2014. Therefore, we think new investors that have previously shunned the story due to the weak cash position and drip financings may start to be attracted to the story starting in 2014. We built a 10-year discounted cash flow model that pegs fair-valuation between $1.50 and $2.00 per share (assumption to be narrowed once the company secures long-term financing).”

For more information on OXYS, visit

Let us hear your thoughts below:

This entry was posted in OxySure Systems Inc. OXYS. Bookmark the permalink.

Comments are closed.